259
Participants
Start Date
October 1, 2015
Primary Completion Date
February 4, 2016
Study Completion Date
February 4, 2016
Placebo ELLIPTA inhaler
The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
Questionnaire
ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
GSK Investigational Site, Baltimore
GSK Investigational Site, Charlotte
GSK Investigational Site, Union
GSK Investigational Site, Miami
GSK Investigational Site, Aventura
GSK Investigational Site, Mobile
GSK Investigational Site, Minneapolis
GSK Investigational Site, Plymouth
GSK Investigational Site, Sunset
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Waco
GSK Investigational Site, San Antonio
GSK Investigational Site, Huntington Beach
GSK Investigational Site, Medford
GSK Investigational Site, North Dartmouth
Lead Sponsor
GlaxoSmithKline
INDUSTRY